As reported above, one of the patients in our trial (P8) developed a T-ALL associated to the integration of the gamma retroviral vector to the proto-oncogene LMO2 (LIM domain only 2) (1). The gene discussed is LMO2; the disease is acute lymphoblastic leukemia.